Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer

Oncologist

Volumn 19, Issue 5, 2014, Pages 459-465

  Schneider, Jeffrey G ^a   Farhadfar, Nosha ^a   Sivapiragasam, Abirami ^a   Geller, Matthew ^a   Islam, Shahidul ^a   Selbs, Elena ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

ERCC1; Lung cancer; Platinum sensitivity; Tumor predictive biomarker

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; PEMETREXED; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASSAY; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETIC SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84900019881     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0311     Document Type: Article

References (42)

1. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
2. Azzoli CG, Baker S Jr., Temin S et al. American Society of Clinical Oncology Clinical Practice Guide-lineupdateonchemotherapyforstageIVnon-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
3. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
4. Butts CA, Ding K, Seymour L et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.
5. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. JClin Oncol 2008;26: 3552-3559.
6. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 2001;19:1734-1742.
7. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-1485.
8. Altaha R, Liang X, Yu JJ et al. Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 2004;14: 959-970.
9. De Silva IU, McHugh PJ, Clingen PH et al. Defining the roles of nucleotide excision repair and recombination in the repair of DNA inters rand cross-links in mammalian cells. Mol Cell Biol 2000; 20:7980-7990.
10. Niedernhofer LJ, Odijk H, Budzowska M et al. The structure-specific end nuclease Ercc1-Xpf is required to resolve DNA inters rand cross-link- induced double-strand breaks. Mol Cell Biol 2004; 24:5776-5787.
11. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006;355:1054-1055.
12. Gazdar AF. DNA repair and survival in lung cancer-The two faces of Janus. N Engl J Med 2007; 356:771-773.
13. Soria JC. ERCC1-tailored chemotherapyinlung cancer: The first prospective randomized trial. J Clin Oncol 2007;25:2648-2649.
14. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR arepredictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-1825.
15. Cobo M, Isla D, Massuti B et al. Customizing cisplatin basedon quantitative excision repair cross-complementing1mRNA expression:Aphase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25: 2747-2754.
16. Holm B, Mellemgaard A, Skov T et al. Different impact of excision repair cross-complementation group1onsurvivalinmale and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009;27: 4254-4259.
17. Jiang J, Liang X, Zhou X et al. ERCC1 expression asaprognostic and predictive factor inpatients with non-small cell lung cancer:Ameta-analysis. Mol Biol Rep 2012;39:6933-6942.
18. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
19. Reynolds C, Obasaju C, Schell MJ et al. Randomized phase III trial of gemcitabine-based chemotherapy withinsitu RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009;27:5808-5815.
20. Vilmar AC, Santoni-Rugiu E, Sørensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010;21:1817-1824.
21. Panel NCCN-NSCLC. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed on August 11, 2013.
22. Friboulet L, Olaussen KA, Pignon JP et al. ERCC1 is form expression and DNArepairinnon-small-cell lung cancer. N Engl J Med 2013;368:1101-1110.
23. Miller AB, Hoogstraten B, Staquet M et al. Reportingresultsofcancer treatment. Cancer 1981; 47:207-214.
24. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
25. Olaussen KA, Fouret P, Kroemer G. ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl J Med 2007;357:1559-1561.
26. Danenberg K, Danenberg PV, Swenson S, inventors; University of Southern California, assignee. Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens. US patent 6 248 535. June 19, 2001.
27. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin CancerRes 2002;8: 2286-2291.
28. Siegel S, Castellan NJ. McGraw H, ed. Non-parametric statistics for the Behavioral Sciences. 2nd ed. New York, NY: McGraw-Hill, 1988.
29. Fleiss JL. Statistical Methods for Rates and Proportions. 3rd ed. New York, NY: John Wiley & Sons, 2003.
30. Park JO, Lee SI, Song SY et al. Measuring responseinsolid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33: 533-537.
31. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer [letter]. N Engl J Med 2007;356:2538-2540; author reply 2540-2541.
32. Booton R, Ward T, Ashcroft L et al. ERCC1mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:902-906.
33. Tan DS, Ng QS, Tan IB et al. Truth about ERCC1in lung cancer [letter]. J Clin Oncol 2010;28:e162; author reply e164.
34. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcita-bine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-4737.
35. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1and ERCC1in lungcancer. N Engl J Med 2007;356:800-808.
36. Tepeli E, Caner V, Buyukpinarbasjli N et al. Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Mol Biol Rep 2012;39:335-341.
37. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14:1797-1803.
38. Friboulet L, Barrios-Gonzales D, Commo F et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 2011;17:5562-5572.
39. Bhagwat NR, Roginskaya VY, Acquafondata MB et al. Immunodetection of DNA repairendonuclease ERCC1-XPF in human tissue. Cancer Res 2009;69: 6831-6838.
40. Panasci LC. Different impact of excision repair cross-complementing group 1 on survival [letter]. J Clin Oncol 2010;28:e163; author reply e164.
41. Felip E, Gridelli C, Baas P et al. Metastatic non-small-cell lung cancer: Consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: First ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011;22: 1507-1519.
42. Holm B, Mellemgaard A, Skov T et al. Reply to L. C. Panasci and D.S.-W.Tanetal. [letter]. J Clin Oncol 2010;28:e164.